Livmarli

Pharma

Ipsen's liver disease drug Bylvay fails biliary atresia trial

Ipsen has reported the failure of liver disease med Bylvay in a phase 3 study that was designed to expand its patient population into biliary atresia.

Kevin Dunleavy Jul 24, 2026 11:00am

Mirum gets 2nd indication for blockbuster hopeful Livmarli

Mar 13, 2024 6:20pm

Mirum ponies up $445M for 2 Travere liver disease drugs

Jul 18, 2023 8:00am

Ipsen pays $952M to acquire Albireo and liver disease med Bylvay

Jan 9, 2023 10:05am

Mirum gets a leg up on Albireo in pediatric liver disease

Oct 24, 2022 3:11pm

Atara's first-in-class allogeneic T-cell therapy nears EU nod

Oct 14, 2022 11:18am